Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048202 | 0.93 | P2RX7 (0.53) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL13047324 | 0.93 | P2RX7 (0.49) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL13046586 | 0.88 | P2RX7 (0.56) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL1591765 | 0.87 | P2RX7 (0.68) | P2RX7POLBMAPTTP53GRM2 | |
| SCHEMBL13047332 | 0.87 | P2RX7 (0.56) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL13046579 | 0.85 | MAPT (0.49) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL1590519 | 0.83 | P2RX7 (0.78) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL13047326 | 0.82 | P2RX7 (0.50) | P2RX7POLBMAPTTP53RAB9A | |
| SCHEMBL1590205 | 0.80 | P2RX7 (0.68) | P2RX7POLBMAPTTP53GRM2 | |
| SCHEMBL1590254 | 0.80 | P2RX7 (0.63) | P2RX7POLBMAPTTP53GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885POLB 3676/4885MAPT 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.